Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBP03 is a live biotherapeutic product (LBP) consisting of formulated bacteria, developed by Shenzhen Xbiome Biotech. As a microbiome-based therapy, it is designed to modulate host-microbiome interactions to produce anti-tumor effects, representing a key component of Xbiome's immuno-oncology pipeline. The drug is developed using an AI-based microbiome platform to identify specific bacterial strains that can influence the tumor microenvironment and enhance the host's immune response against cancer. LBP03 is currently in Phase 1 clinical development for the treatment of various solid tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LBP03.